The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys
Open accessAbstract
BACKGROUND: Population-based data on COVID-19 are essential for guiding policies. There are few such studies, particularly from low or middle-income countries. Brazil is currently a hotspot for COVID-19 globally. We aimed to investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence by city and according to sex, age, ethnicity group, and socioeconomic status, and compare seroprevalence estimates with official statistics on deaths and cases. METHODS: In this repeated cross-sectional study, we did two seroprevalence surveys in 133 sentinel cities in all Brazilian states. We randomly selected households and randomly selected one individual from all household members. We excluded children younger than 1 year. Presence of antibodies against SARS-CoV-2 was assessed using a lateral flow point-of-care test, the WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech, Guangzhou, China), using two drops of blood from finger prick samples. This lateral-flow assay detects IgG and IgM isotypes that are specific to the SARS-CoV-2 receptor binding domain of the spike protein. Participants also answered short questionnaires on sociodemographic information (sex, age, education, ethnicity, household size, and household assets) and compliance with physical distancing measures. FINDINGS: We included 25 025 participants in the first survey (May 14-21) and 31 165 in the second (June 4-7). For the 83 (62%) cities with sample sizes of more than 200 participants in both surveys, the pooled seroprevalence increased from 1·9% (95% CI 1·7-2·1) to 3·1% (2·8-3·4). City-level prevalence ranged from 0% to 25·4% in both surveys. 11 (69%) of 16 cities with prevalence above 2·0% in the first survey were located in a stretch along a 2000 km of the Amazon river in the northern region. In the second survey, we found 34 cities with prevalence above 2·0%, which included the same 11 Amazon cities plus 14 from the northeast region, where prevalence was increasing rapidly. Prevalence levels were lower in the south and centre-west, and intermediate in the southeast, where the highest level was found in Rio de Janeiro (7·5% [4·2-12·2]). In the second survey, prevalence was similar in men and women, but an increased prevalence was observed in participants aged 20-59 years and those living in crowded conditions (4·4% [3·5-5·6] for those living with households with six or more people). Prevalence among Indigenous people was 6·4% (4·1-9·4) compared with 1·4% (1·2-1·7) among White people. Prevalence in the poorest socioeconomic quintile was 3·7% (3·2-4·3) compared with 1·7% (1·4-2·2) in the wealthiest quintile. INTERPRETATION: Antibody prevalence was highly heterogeneous by country region, with rapid initial escalation in Brazil's north and northeast. Prevalence is strongly associated with Indigenous ancestry and low socioeconomic status. These population subgroups are unlikely to be protected if the policy response to the pandemic by the national government continues to downplay scientific evidence. FUNDING: Brazilian Ministry of Health, Instituto Serrapilheira, Brazilian Collective Health Association, and the JBS Fazer o Bem Faz Bem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Analysis of Complex Survey Samples
Lumley, T. (2004) · Journal of Statistical Software · doi:10.18637/jss.v009.i08 · Cited by 2,425
Chronic non-communicable diseases in Brazil: burden and current challenges
Schmidt, M. I., Duncan, B. B., e Silva, G. A., Menezes, A. M., Monteiro, C. A., Barreto, S. M., Chor, D., & Menezes, P. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60135-9 · Cited by 1,606
Self-citationSpread of SARS-CoV-2 in the Icelandic population
Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006100 · Cited by 1,248
Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc8413 · Cited by 868
Pena, S. D. J., Di Pietro, G., Fuchshuber-Moraes, M., Genro, J. P., Hutz, M. H., Kehdy, F. D. S. G., Kohlrausch, F., Magno, L. A. V., Montenegro, R. C., Moraes, M. O., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017063 · Cited by 677
Baqui, P., Bica, I., Marra, V., Ercole, A., & van der Schaar, M. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30285-0 · Cited by 629
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Whitman, J. D., Hiatt, J., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0659-0 · Cited by 454
The Role of Antibody Testing for SARS-CoV-2: Is There One?
Theel, E. S., Slev, P., Wheeler, S., Couturier, M. R., Wong, S. J., & Kadkhoda, K. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00797-20 · Cited by 305
Research works printed but not linked: 7
- Barreto, 2020, What is urgent and necessary to inform policies to deal with the COVID-19 pandemic in Brazil?, Revista Brasileira de Epidemiologia, 23
- 2020, COVID-19 in Brazil: “So what?”, Lancet, 395
- Whitman, 2020, Test performance evaluation of SARS-CoV-2 serological assays, medRxiv
- 2020, COVID-19 in Africa: no room for complacency, Lancet, 395
- Pereira, 2020, Fases da pandemia em 6 capitais da Amazônia brasileira, ODS Atlas Amazonas, 2, 1
- Aleixo, 2020, Along waterways: mobility and evolution of COVID-19 in the state of Amazonas, Confins, 45
- Campos, 2017, Differences in mortality between indigenous and non-indigenous persons in Brazil based on the 2010 Population Census, Cad Saude Publica, 33
Cited by
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., et al. (2021) · Science · doi:10.1126/science.abe9728 · Cited by 488
Ranzani, O. T., Bastos, L. S. L., Gelli, J. G. M., Marchesi, J. F., Baião, F., Hamacher, S., & Bozza, F. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30560-9 · Cited by 513
On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community
Goldstein, E., Lipsitch, M., & Cevik, M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa691 · Cited by 355
Spatiotemporal pattern of COVID-19 spread in Brazil
Castro, M. C., Kim, S., Barberia, L., Ribeiro, A. F., Gurzenda, S., Ribeiro, K. B., Abbott, E., Blossom, J., Rache, B., & Singer, B. H. (2021) · Science · doi:10.1126/science.abh1558 · Cited by 342
Metadata
- Authors
- Hallal, P. C., Hartwig, F. P., Horta, B. L., Silveira, M. F., Struchiner, C. J., Vidaletti, L. P., Neumann, N. A., Pellanda, L. C., Dellagostin, O. A., Burattini, M. N., Victora, G. D., Menezes, A. M. B., Barros, F. C., Barros, A. J. D., & Victora, C. G.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 8
- Issue
- 11
- Pages
- e1390-e1398
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W3087050596
- Cited by
- 398
- References
- 23
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Instituto Serrapilheira
- Associação Brasileira de Saúde Coletiva
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. https://app.cochat.ai/papers/10.1016/s2214-109x(20)30387-9
- The paper
- Hallal, P. C., Hartwig, F. P., Horta, B. L., Silveira, M. F., Struchiner, C. J., Vidaletti, L. P., Neumann, N. A., Pellanda, L. C., Dellagostin, O. A., Burattini, M. N., Victora, G. D., Menezes, A. M. B., Barros, F. C., Barros, A. J. D., & Victora, C. G. (2020). SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(20)30387-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.